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The objective of this study is to identify the changes of metabolites in the rat endometriosis models treated with Gui-Zhi-Fu-Ling-
capsules (GZFLC), a classic Chinese medicinal formula, and to explore the effects of GZFLC on the serum levels of transforming
growth factor-𝛽1 (TGF-𝛽1) and the mRNA expression levels of vascular endothelial growth factor (VEGF) and glucose transporter
4 (GLUT-4) in the endometriotic tissues. Forty female Wistar rats were randomly divided into the sham-operation group (Normal
group),Model group,Danazol group, andGZFLC group.The serum levels of TGF-𝛽1 weremeasured using enzyme-linked immune-
sorbent assay (ELISA). The mRNA expression levels of VEGF and GLUT-4 in the endometriotic tissue of the rat endometriosis
models were measured using real-time quantitative PCR. The metabolites in urine were detected by 1H NMR method. Eight
identified metabolites of the NMR resonance were involved in the glycolysis metabolism. Among the 8 metabolites, Lactate,
Acetate, TMA, and Formate were downregulated with GZFLC. Citrate, TMAO, Taurine, and Hippurate were unregulated with
GZFLC. The serum levels of TGF-𝛽1 in the Danazol and GZFLC groups were significantly higher than those of Normal group and
significantly lower than theModel group.GZFLC treatment significantly decreased theGLUT-4 andVEGFmRNAexpression levels
in the endometriotic tissues of the endometriosis rats (P < 0.05). GZFLC significantly decreased the GLUT-4 mRNA expression
levels in rats of GZFLC group compared with Danazol group. It is through regulating the metabolites changes of glycolysis or
gluconeogenesis that GZFLC significantly affected the expression levels of TGF-𝛽1, GLUT-4, and VEGF of the model rats with
endometriosis.
1. Introduction
Endometriosis is the most common gynecological disease,
which is characterized by the growth of endometrial tissue at
ectopic locations [1]. It is a chronic condition characterized by
the presence of endometrial tissue outside the uterine cavity,
most commonly on the pelvic peritoneum and ovaries [2, 3].
Endometriosis can result in substantial morbidity, including
pelvic pain, multiple operations, and infertility [3]. Endome-
trial tissue is characterized by an exaggerated inflammatory
environment around ectopic tissues [4, 5]. Endometriosis
affects approximately 10% of women of reproductive age
[3, 6]. About 30% of the patients are asymptomatic and
the incidence of infertility among women suffering from
endometriosis ranges from 30%-40% [6]. Increased peri-
toneal fluids concentrations of cytokines that lead to the
migration, proliferation, and activation of macrophages have
been reported in patients with endometriosis [7, 8]. Surgery
provides relief to women in pain, but symptoms recur in 75%
of cases within 2 years [9].
Although surgical and hormonal treatment are ap-
plied as the common interventions, the unpleasant side
effects and high rates of relapse limited the range of
these interventions [10, 11]. Some traditional Chinese
medicinal herbs, such as Bupleurum (Chinese name, Chai
hu) and Chinese angelica (Chinese name, Dang Gui),
have significant curative effects in treating endometriosis
[12, 13]. For traditional Chinese medicinal formulas,
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Gui-Zhi-Fu-Ling formula, Dang-Gui-Shao-Yao-San, Jia-
Wei-Xiao-Yao-San are the most frequently prescribed
Chinese herbal products (CHPs) to treat endometriosis
[14].
Gui-Zhi-Fu-Ling-Wan (GZFLW) is a classic Chinese
medicinal formula, which was firstly described in Essential
Prescriptions from the Golden Cabinet (Jingui Yaolue) by
an ancient Chinese doctor, Zhong-Jing Zhang, Han Dynasty
(300 A.D.) [15–17]. GZFLW is one of the top ten most
frequently prescribed CHPs used to relieve endometriosis-
related symptoms [14]. GZFLW consists of five herbs: Ramu-
lus Cinnamomi, Poria, Semen Persicae, Radix Paeoniae
Rubra or Radix Paeoniae Alba, and Cortex Moutan. The tra-
ditional effects of GZFLW are invigorating blood, dissolving
stasis, and resolving masses [15] and it has sedative and anti-
inflammatory effects on endometriosis-related symptoms
[14]. Gui-Zhi-Fu-Ling Capsules (GZFLC) originate from the
classic Chinese medicinal formula, GZFLW, which is more
convenient to be taken and easily accepted by majority of the
patients.
The metabolic disorder has been found to play an
important role in the development of endometriosis, and
rats' urinary metabolomes have revealed the potential roles
of CHPs in management of metabolic disorder [18, 19].
Metabonomics is a scientific discipline that can be used to
study changes in the metabolite ensembles associated with
disease pathophysiology [20]. 1H-NMRbasedmetabolomics,
a rapid and noninvasive approach, to identify metabolic
changes associated with endometriosis in urine samples, is
useful to get a better understanding of the pathogenesis of
endometriosis, thus providing support to the noninvasive
diagnosis of this pathology [21]. Few studies have been
conducted on the mechanism and the functions of GZFLC
in relation to the metabolic changes in pelvic endometriosis.
Therefore, the present study was then designated to identify
the changes of metabolites in the rat endometriosis models
treated with GZFLC and to explore the effects of GZFLC on
the levels of TGF-𝛽1 and the mRNA expression levels of vas-
cular endothelial growth factor (VEGF) in the endometriotic
tissues.
2. Materials and Methods
2.1.Materials. GZFLC is aChinese formula, composed of five
Chinese medicinal plants, Cinnamomum cassia Blume (Cin-
namomi cortex), Paeonia lactiflora Pallas (Paeoniae radix),
Paeonia suffruticosa Andrews (Moutan cortex), Prunus per-
sica Batsch (Persicae semen), and Poria cocos Wolf (Hoe-
len). The capsules of GZFLC were purchased from Beijing
Tong Ren Tang Limited, China. The voucher specimens of
GZFLC were deposited in the laboratory of College of Food
Science and Biotechnology, Zhejiang Gongshang University,
Hangzhou, China. The dried powder of the capsules was sus-
pended in 0.5% sodium carboxymethyl cellulose (CMC Na)
before being administered orally with the dose of 40mg/kg
body weight to rats. The oral dosage for rats was calculated
according to the patients dosages of GZFLC used 2.7g per
day. Danazol was provided by Lianhua Medicine Company
(Jiangsu, China).
2.2. Establishment of the Model Rats with Endometriosis. 40
female Wistar rats with body weight of 160 ±20 g were
purchased from the Laboratory Animal Center of Zhe-
jiang Chinese Medical University (Hangzhou, China). The
experimental protocol was approved by Zhejiang Gongshang
University. The animal’s welfare was monitored according
to the Guide for the Care and Use of Laboratory Animal
of the National Institute of Health (Publication No. 80–23,
revised 1996). We attempt to minimize suffering of animals
and reduce the numbers of animal in the study. Among
the 40 rats, 10 rats were randomly taken as the Normal
control group.Themethod of establishing themodel rats with
endometriosis was based on our previous studies [22–25].
Four weeks after the endometriosis model were made, the 30
model rats were randomly divided into three groups (n=10 in
each group) including model control group (Model group),
GZFLC group, and Danazol group. After all the treatment
ended, the 40 rats were all sacrificed.
2.3. Group and Administration. The 40 rats were divided into
four groups: GZFLC group (the rats were orally adminis-
trated with the extracts of GZFLC at 40 mg/kg once daily
for 30 consecutive days), Danazol group (the rats were orally
administrated with Danazol at 36 mg/kg once daily for 30
consecutive days), Model Control group (Model group, the
rats were orally administrated with saline at 8ml/kg once
daily for 30 consecutive days), and Normal group (the rats
were orally administrated with saline at 8ml/kg once daily
for 30 consecutive days). After all the treatment ended, the
rats were sacrificed and the samples of endometriotic tissue
and the serum were taken. A total of 0.1g endometriotic
tissue was collected and stored in TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) and stored frozen at −80∘C until being
used for further evaluation. The endometriotic tissue was
homogenized in the tissue homogenizer. Then CCL
4
was
added and centrifuged at 12,000 rpm for 7 min at 4∘C. The
supernatants were collected and stored frozen at −80∘C until
being used for further evaluation. After GZFLC o.a. for 30
consecutive days, at day 31, urine samples were collected
in metabolism cages overnight from all groups and then
frozen at −20∘C and stored until analysis. The levels of
Lactate in urine were detected by NMR. The serum levels of
transforming growth factor-𝛽1 (TGF-𝛽1) were detected with
ELISA. The mRNA expression levels of vascular endothelial
growth factor (VEGF) and glucose transporter 4 (GLUT-4)
were detected with qPCR.
2.4. Rat Urine Sample Preparation. Urine samples were
collected in metabolism cages overnight from all groups.
Then, urine samples were frozen at −20∘C and stored until
analysis. A 1ml aliquot of each of the urine samples was
taken for 1H-NMR spectroscopy. To reduce pH induced
chemical shift variability in the urine samples, 200𝜇L of









were added to 500𝜇L urine then centrifuged at 8000x g for
5 min. 10𝜇L of sodium trimethylsilyl propionate (TSP) and
50𝜇L of deuterium oxide (D
2
O) were added to 550𝜇L of the
supernatant. TSP was used as a chemical shift reference. 10%
D
2
O was used as a lock solvent for high resolution for NMR
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for NMR automation [26].
2.5. 1𝐻 NMR Analysis of Metabolites in Urine. All the 1H
NMR spectra were acquired from Bruker 600 MHz spec-
trometer (Bruker BioSpin, Germany). Free induction decay
was zero filled to 64 K points then multiplied with an
exponential function to 1.0 Hz line-broadening factor before
Fourier transformation. The 1H NMR spectra between 𝛿 0.5
and 10.0 were segmented into consecutive nonoverlapping
regions of 𝛿 0.002 chemical shift bins. We chose the bin
size of 𝛿 0.002 as the primary chemical shift width for the
identification of metabolites and integrated the spectral area
in each bin, which can avoid the encompassment of several
peaks and have clear peak multiplicities. The water resonance
of 𝛿 4.50–5.23 and urea resonance of 𝛿 5.46–6.25 were
excluded to eliminate baseline effects. We use the division
of integrated segment with the total area of the spectrum to
compensate the differences of concentration [27]. The peak
area of each bin was calculated.
2.6. Multivariate Statistical Techniques of 1𝐻 NMR Data.
Multivariate analysis of 1H NMR data was analyzed with
SIMCA-P+ (version 11.5.0.0; Umetrics AB, Umea˚, Sweden).
Mean centered integral values were used for the principal
component analysis (PCA), partial least square discriminant
analysis (PLS-DA), and OPLS-DA analysis. Unsupervised
PCA was used for the data of initial visualization. PLS-DA
was used for the further trends of the data.The quality of PLS-
DA models was analyzed using R2 and Q2, where R2 is the
estimate of goodness-of-fit of model to the data, while Q2 is
the estimate of goodness of prediction.
2.7. Determination of TGF-𝛽1 in Serum. 2 ml of blood was
drown in polypropylene tubes and was allowed to clot for 30
minutes before centrifugation. The serum was obtained by
centrifugation for 10 minutes at approximately 1000 g. The
samples were stored at - 70∘C before the measurements (not
longer than 3 months). Serum TGF-𝛽1 concentrations were
measured using commercially available ELISA kit (Neobio-
science, Shen-zhen, China).
2.8. Detection of GLUT-4 and VEGF mRNA Expression Levels
in Endometriotic Uterus Tissue. A total of 0.1g endometriotic
tissue was collected and stored in TRIzol reagent (Invitrogen,
Carlsbad, CA, USA). The tissue was homogenized in the
tissue homogenizer (30 s at 4.0 m/s). The relative expression
was determined by quantitative real-time PCR (Q-RT PCR)
in an ABI Step-one Sequence Detection System (Applied
Biosystems, Forrest City, CA, USA). The total RNA was iso-
lated with RNAiso reagent (Takara Biotechnology, Dalian,
China) according to the instructions of the manufacturer.
The purity and concentration of the RNAs were determined
by OD260/280 readings with a NanoDrop ND-100 spec-
trophotometer (Thermo Fisher Scientific Inc., Waltham, MA,
USA). The ratio of absorbance at 260 nm and 280 nm is
used to assess the purity of DNA and RNA. A ratio of 1.8-
2.0 is generally accepted as pure for RNA. The cDNA was
prepared from 500 ng total RNA by reverse transcription
(RT) with the PrimeScript RT Reagent kit (Perfect Real
Time; Takara Biotechnology). The cDNA samples were then
diluted in DNase- and RNase-free water at a proportion
of 1:3 prior to further analysis. For the mRNA quantifica-
tion, the normalized Ct of each gene was compared with
the endometriotic tissue of control group mRNA. The rat
GLUT-4 and VEGF gene-specific primers were provided
by Sangon Biological Engineering Technology (Shanghai,
China). PCR reactions were performed in a final volume of
25 𝜇l containing 50 ng of templates complementary DNA
(cDNA) and 2.5 𝜇l of 10× PCR buffer real-time polymerase
chain reaction (PCR) amplifications for GLUT-4 and VEGF
were conducted using One-Step SYBR PrimeScript RT-
PCR Kit according to the manufacturer's instructions under
the following conditions: 95∘C for 5min, followed by 40
cycles of 95∘C for 5s and 60∘C for 10s. Polymerase chain
reaction products of 𝛽-actin primer gene were used as an
internal standard. Specificity of amplification was confirmed
by melt curve analysis. After normalization against 𝛽-actin
mRNA, the comparative threshold (CT) method (i.e., ΔΔCT
method) was used to quantify the relative expression levels
of the samples. Fold changes were calculated using the
equation 2-ΔΔCT. Q-RT PCR experiments were repeated
three times independently. Data are represented as the mean
±SD.
2.9. Statistical Analysis. Processing of the NMR spectra was
performed by comparing spectral overlays using Topspin 3.0
(Bruker Biospin). The shifting signals were aligned in MAT-
LAB 7.13 (MathWorks, Inc., Natick, MA, USA). Regular and
dynamic bins were applied. Dynamic bins were determined
with MATLAB for the Dynamic Adaptive Binning (DAB)
Algorithm (Anderson et al., 2011).The statistical analysis was
conducted using the Simca-P+ software (Umetrics, Umea˚,
Sweden). Data were analyzed using the Statistical Package for
Social Sciences (SPSS 22.0 for Windows). The comparisons
of different groups were performed with one-way analysis
of variance (ANOVA) and multiple comparison tests with
Bonferroni correction procedure. For all the hypothesis tests,
significance level was set at P=0.05 and two-tailed tests were
used.
3. Results
3.1. 1𝐻 NMR Metabolomic Analysis of Urine Samples. The
urine samples were subjected to 1H NMR analysis to inves-
tigate the metabolic changes in the urine caused by GZFLC
treatment. All the ratswere divided randomly into two groups
for NMR analysis, with 8 rats in each group: A, control group
(endometriosis model rats without any treatment; B, GZFLC
group, endometriosis model rats with GZFLC treatment.
Representative 600MHz 1H NMR spectra (𝛿 0.5-4.7, 5.0-
9.6) from group A and group B were shown in Figure 1.
Data obtained from the 1H NMR spectra were analyzed.
The data were subsequently analyzed using multivariate
statistics (PCA, PLS-DA, and OPLS-DA). The metabolites
were identified based on data obtained from database of
Human Metabolome Database (HMDB).

























































































































































































Figure 1: 600 MHz 1H-nuclear magnetic resonance spectra (𝛿 0.5-4.7, 5.0-9.6) of urine samples obtained from (A) control group, (B)













Figure 2: Principal component analysis (PCA) scores plot PC vs.
PC2 obtained from 1H NMR spectra of urine samples from two
groups, (A) control group, (B) GZFLW group. The ellipse repre-
sents 95% confidence region of the model based on HotellingT2.
R2X=82.2%, Q2=0.54.
The PCA scores plots of 1H NMR data in Figure 2 give
an overview of the profiles for the respective treatments. The
PCA and PLS-DA score plots were visualized with the first
principal component (PC) and the second principal compo-
nent (PC2). Based on R2X=82.2%, Q2=0.54 (Figure 2), the
mathematical model is effective. The clustering phenomenon
between the two groups is obvious. There is significant
difference between the control group and the GZFLC group.
3.2. Discrimination between the Control and GZFLC Groups
Using 1𝐻 NMR. The PLS-DA was based on a unit vari-
ance scaling strategy. A 10-fold cross-validation was used
to validate the PLS-DA model, which was performed to
evaluate the quality of the model by parameters R2X, R2Y,
and Q2. R2X represents the total variation in X and describes
the optimization of the analytical model. R2Y represents
the variation in the response variable Y. Q2 represents the
predictive ability of the model and the authenticity of the
predicted results. On the scores plot, each point represented
an individual sample. The center and the margin of each
ellipse indicate mean and standard deviation, respectively. A
permutation test from the verification plots was performed
to validate the degree of overfitting for the PLS-DA model.
The correlation coefficient between the original Y and the
permutated Y was plotted against the cumulative R2 and
Q2; a regression line was calculated with the R2 and Q2
intercept limits. These tests compared the goodness-of-fit of
the original model with the goodness-of-fit of several models
based on data in which the order of the Y observations
was randomly permutated while the X matrix remained
constant. In the verification plots, the Y-axis represents R2
(green triangle) and Q2 (blue box) and the X-axis designates
the Pearson correlation coefficient between the original and
permutated rank-ripeness. When the Q2 regression line had
a negative intercept and R2 values on the left were lower than
the original points on the right, the validation plots of the
PLS-DAmodel were effective. The scores plots and validation
plots of PLS-DA are shown in Figure 3. Based on the PLS-DA
models in Figure 3, groupAandBwere discriminatedwith an
R2X of 0.448, an R2Y of 0.959, and a Q2 of 0.904. The results
showed that the original PLS-DA models were effective. As
shown in Figure 3, there is significant difference between the
rats of the control group and the GZFLC group.
OPLS-DA plots were visualized with the first principal
component (t[1]) and the orthogonal component (t[2]). The
parameters Q2 and R2X were computed to test the validity of
the model against overfitting, where R2X is the total variation
explained in the data and Q2 is the cross-validated explained
variation with increasing reliability as Q2 approaches 1. The
sixfold cross-validation method and permutation test for 500
times with the first component were carried out to measure
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Figure 3: Scores plot (top) and validation plot (bottom) of partial least squares discriminant analysis (PLS-DA)models from two groups. (A)






























Figure 4: OPLS-DA scatter plots derived from 1H NMR spectra of the two groups. Notes: (A) control group(◼), (B) GZFLW group(e).
R2X=0.448 and Q2=0.904. The vertical axis of the validation plots represented the R2 and Q2 values, and the horizontal axis represented the
correlation coefficients.
the robustness of the model, where if Q2 (max) obtained
from permutation test is less than or equal to Q2 (cum)
obtained from OPLS-DA, the established OPLS-DA model
is robust. Based on the OPLS-DA models, the rats in the
control and GZFLC group were discriminated with R2X =
44.8% and Q2 = 0.904. In OPLS-DA scores plots, significant
biochemical differences were also observed between the two
groups (Figure 4).
By assessing the coefficient plots of OPLS-DA in Figure 4,
the main metabolites contributing to the separation of the
two groups were shown in Table 1. Among the 8 metabolites,
Lactate, Acetate, TMA, and Formate were downregulated
with GZFLC. Citrate, TMAO, Taurine, and Hippurate were
upregulated with GZFLC. At the end of the study, the
two groups were subjected to NMR metabolomic studies.
8 metabolites were identified by fully mapping of chemical
shifts, coupling patterns, and coupling constants to previously
reported data. In Table 1, discriminating metabolites (with
respect to the control group) of the group treated with
GZFLC were presented. Eight identified metabolites of the
NMR resonance, including Lactate, Acetate, Citrate, TMA
(Trimethylamine N), TMAO (Trimethylamine N-oxide),
Taurine, Hippurate, and Formate are involved in glycolysis
and other metabolisms.
3.2.1. Identification of Predicative Metabolite Pathways. To
determine metabolic pathways which were affected by
GZFLC, the metabolites Lactate, Acetate, Citrate, TMA
(Trimethylamine N), TMAO (Trimethylamine N-oxide),
Taurine, Hippurate, and Formate (Table 1) were mapped with
Simca-P+ software. The metabolic pathways were presented
graphically as a bubble plot in Figure 5. In Table 2, the
pathways and functional analysis in the bubble plot are
summarized: (A) Glyoxylate and dicarboxylate metabolism;
(B) Pyruvate metabolism; (C) Glycolysis or Gluconeogene-
sis; (D) Taurine and hypotaurine metabolism; (E) Methane
metabolism; (F) Citrate cycle (TCA cycle); and (G) Pri-
mary bile acid biosynthesis. The top three pathways and
functional metabolites are (A) Glyoxylate and dicarboxylate
metabolism; (B) Pyruvate metabolism; and (C) Glycolysis
or Gluconeogenesis. Based on the KEGG databases and the
pathways and functional analysis of metabolites, glycolysis or
gluconeogenesis has the most total numbers of compounds
in the pathway.
3.2.2. The Serum Levels of TGF-𝛽1. As shown in Figure 6,
the serum levels of TGF-𝛽1 in Danazol group and GZFLC
group were significantly higher than those of Normal group
(P<0.05) and significantly lower than the Model group
(P<0.05). No marked difference existed between the GZFLC
and Danazol groups (P>0.05).
3.2.3. GLUT-4 and VEGF Gene Expression Levels in the
Endometriotic Tissues. For the GLUT-4 mRNA expression
levels, it was significantly higher in the Danazol and the
Model groups compared with the Normal group (P<0.05)
(Figure 5). For the GLUT-4 and VEGF mRNA expression
levels, there were no significant differences between the
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Table 1: Discriminating metabolites (with respect to the control group) of the treated group with GZFLC.
No. Metabolites Chemical shift Correlation Coefficients HMDB PubChem KEGG
1 Lactate 1.33 -0.676 HMDB0000190 107689 C00186
2 Acetate 1.91 -0.967 HMDB0000042 176 C00033
3 Citrate 2.55 +0.675 HMDB0000094 311 C00158
4 TMA (Trimethylamine N) 2.88 -0.745 HMDB0000906 1146 C00565
5 TMAO (Trimethylamine N-oxide) 3.27 +0.737 HMDB0000925 1145 C01104
6 Taurine 3.42 +0.796 HMDB0000251 1123 C00245
7 Hippurate 7.56 +0.668 HMDB0000714 464 C01586
8 Formate 8.46 -0.863 HMDB0000142 284 C00058
Table 2: Pathways and functional analysis of metabolites.
Pathway Totala Hitsb Raw pc -ln(p) Holm adjust FDR Impactd
A Glyoxylate and dicarboxylate metabolism 16 2 0.003287 5.7179 0.26623 0.23354 0.40741
B Pyruvate metabolism 22 2 0.006219 5.0801 0.49752 0.23354 0.05583
C Glycolysis or Gluconeogenesis 26 2 0.00865 4.7502 0.68333 0.23354 0.02862
D Taurine and hypotaurine metabolism 8 1 0.044858 3.1043 1 0.81549 0.42857
E Methane metabolism 9 1 0.050339 2.989 1 0.81549 0
F Citrate cycle (TCA cycle) 20 1 0.10884 2.2178 1 1 0.05356
G Primary bile acid biosynthesis 46 1 0.23476 1.4492 1 1 0.02976
The predicative pathways are (A) Glyoxylate and dicarboxylate metabolism; (B) Pyruvate metabolism; (C) Glycolysis or Gluconeogenesis; (D) Taurine and
hypotaurine metabolism; (E)Methane metabolism; (F) Citrate cycle (TCA cycle); and (G) Primary bile acid biosynthesis. Based on the pathways and functional
analysis of metabolites, Glycolysis or Gluconeogenesis has the most total number of compounds in the pathway based on the KEGG databases.
aThe total number of compounds in the pathway based on the KEGG databases.
bThe actual matched names and numbers of the predicted metabolites.
cThe P value calculated from the analysis.
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Figure 5: Metabolite pathwaymapping of the involved metabolites.The predicative pathway analysis was performed with Simca-P+ software.
The results are presented graphically as a bubble plot. The more Darker-color and bigger area of the bubbles represents the more significant
metabolite changes in the corresponding pathway.






















































Figure 6: (Left)The serum level of transforming growth factor-beta 1 (TGF-𝛽1). (Right) Glucose transporter (GLUT) and vascular endothelial
growth factor (VEGF) mRNA expression levels in the endometriotic tissues. Data were shown as mean ± SD (N=10 in each group). The
significant differencewas set at aP < 0.05, comparedwith theNormal group; bP<0.05, comparedwith theModel group; and cP<0.05, compared
with the Danazol group.
GZFLC group and the Normal group. Compared with the
Model group, the GLUT-4 and VEGF mRNA expression
levels in the endometriotic tissue were significantly lower
in the other groups (P<0.05). The Model group displayed
the highest GLUT-4 and VEGF mRNA expression levels in
the endometriotic tissues among all the groups. The GZFLC
treatment significantly decreased the GLUT-4 and VEGF
mRNA expression levels in the endometriotic tissues of the
endometriosis rats (P<0.05). GZFLC significantly decreased
the GLUT-4 mRNA expression levels in the rats of GZFLC
group compared with the Danazol group (P<0.05).
4. Discussion
The present study focuses on the use of proton nuclear
magnetic resonance spectroscopy based targeted metabolite
profiling approach to explore metabolites changes expres-
sion for the rats with endometriosis treated with Chinese
formula GZFLC. Furthermore, association of glycolysis with
the metabolite ensembles was also investigated. Xia Liu et
al. found Herba Rhodiolae, a different traditional Chinese
medicine, has similar infect on the glycolysis metabolisms
[28]. In the present study, we identified eight metabo-
lites of the NMR resonance involved in the glycolysis
and other metabolisms, which were treated with different
medicine Gui-Zhi-Fu-Ling-capsules (GZFLC). Among the
8 metabolites, Lactate, Acetate, TMA, and Formate were
downregulated with GZFLC. Citrate, TMAO, Taurine, and
Hippurate were unregulated with GZFLC. Based on the
KEGG databases and the pathways and functional analysis of
metabolites, glycolysis or gluconeogenesis has the most total
numbers of compounds in the pathway.
Glycolysis is an energy-producingmechanism that occurs
in almost all cells and requires an adequate uptake of
glucose mediated by glucose transporter (GLUT) proteins
[29]. Increased glucose metabolism and defects in the mito-
chondrial respiratory system are suggested to be the possible
sources of excessive reactive oxygen species generation in
endometriosis [20]. Endometriotic lesions induced glycol-
ysis, but limited metabolites related researches have been
focused on this. Little is known about GLUT proteins expres-
sion either in the endometrium or the endometriotic lesions.
Via glycolysis pathway, TGF-𝛽 induces the metabolic
conversion of glucose to Lactate, a process referred to
as the “Warburg effect” [30]. Overproduction of Lactate
increases cell invasion, angiogenesis, and immune suppres-
sion, all crucial steps in the development known regulators
of endometriosis [31]. TGF-𝛽 is believed to play a major
role in the etiology of peritoneal endometriosis [9]. Also,
TGF-𝛽1 stimulated glucose transport and induces changes in
the metabolic phenotype of peritoneal mesothelial cells from
women with endometriosis.
Adequate glucose uptake andmetabolism are essential for
the proper differentiation of the uterine endometrium toward
a receptive state capable of supporting embryo implantation.
The inducible nature of GLUT-4 and its limited cellular
expression may make GLUT-4 an attractive target for non-
hormone-based treatments of endometriosis [29]. TGF-beta
and VEGF are released by inflammatory process cells which
may serve as the source of wide spectrum of inflammatory
mediators and growth factors [32].
In the proton NMR study, based on the KEGG databases
and the pathways and functional analysis of metabolites
using, glycolysis or gluconeogenesis has the most total
numbers of compounds in the pathway. At the meanwhile,
we found that the serum levels of TGF-𝛽1 in the Danazol
and GZFLC groups were significantly higher than those
of Normal group and significantly lower than the Model
group. GZFLC treatment significantly decreased the GLUT-
4 and VEGF mRNA expression levels in the endometriotic
tissues of the endometriosis rats. Compared with Danazol
group, GZFLC significantly decreased the GLUT-4 mRNA
expression levels in rats of GZFLC group.
To conclude, GZFLC significantly affected the expression
levels of TGF-𝛽1, GLUT-4, and VEGF of the model rats with
endometriosis, accompanied by regulating the metabolites
8 Evidence-Based Complementary and Alternative Medicine
changes of glycolysis. We hypothesized that GZFLC regulates
endometriosis by effect on glycolysis or gluconeogenesis.
However, more studies should be conducted to explore the
underling molecular and metabolism mechanism further.
Data Availability
The data used to support the findings of this study are
available from the corresponding author upon request.
Conflicts of Interest
The authors declare no conflicts of Interest.
Acknowledgments
This work was supported by Zhejiang Provincial Natural
Science Foundation of China (Grant No. LH19H290001); the
State Scholarship Fund (File No. 201708330448) awarded by
the China Scholarship Council; Zhejiang TCM Foundation
(No. 2014ZA072); the Doctoral Program ofHigher Education
of China (No. 20133326120006); the Opening Foundation of
Food Science and Engineering the most important discipline
of Zhejiang province (Grant No. JYTsp20142013), Zhejiang
Provincial Collaborative Innovation Center of Food Safety
and Nutrition (Grant No. 2017SICR117).
References
[1] W. Cheng, L. Chen, S. Yang et al., “Puerarin suppresses pro-
liferation of endometriotic stromal cells partly via the MAPK
signaling pathway induced by 17ss-estradiol-BSA,” PLoS ONE,
vol. 7, no. 9, Article ID e45529, 2012.
[2] L. C. Giudice, “Clinical practice. Endometriosis,” The New
England Journal of Medicine, vol. 362, no. 25, pp. 2389–2398,
2010.
[3] L. C. Giudice and L. C. Kao, “Endometriosis,” The Lancet, vol.
364, no. 9447, pp. 1789–1799, 2004.
[4] K. Tomio, K. Kawana, A. Taguchi et al., “Omega-3 Polyunsat-
urated Fatty Acids Suppress the Cystic Lesion Formation of
Peritoneal Endometriosis in Transgenic Mouse Models,” PLoS
ONE, vol. 8, no. 9, p. e73085, 2013.
[5] X. Qi, Y. Zhang, H. Ji et al., “Knockdown of prohibitin expres-
sion promotes glucose metabolism in eutopic endometrial
stromal cells from women with endometriosis,” Reproductive
BioMedicine Online, vol. 29, no. 6, pp. 761–770, 2014.
[6] T.C.Okeke, L.C. Ikeako, andC.C. Ezenyeaku, “Endometriosis,”
Nigerian Journal of Medicine, vol. 20, no. 2, pp. 191–199, 2011.
[7] S. J. Weil, S. Wang, M. C. Perez, and C. R. Lyttle, “Chemotaxis
of macrophages by a peritoneal fluid protein in women with
endometriosis,” Fertility and Sterility, vol. 67, no. 5, pp. 865–869,
1997.
[8] K. L. Sharpe-Timms, P. L. Bruno, L. L. Penney, and J. T.
Bickel, “Immunohistochemical localization of granulocyte-
macrophage colony-stimulating factor inmatched endometrio-
sis and endometrial tissues,” American Journal of Obstetrics &
Gynecology, vol. 171, no. 3, pp. 740–745, 1994.
[9] C. O. Omwandho, L. Konrad, G. Halis, F. Oehmke, and H.
Tinneberg, “Role of TGF- s in normal human endometriumand
endometriosis,”Human Reproduction, vol. 25, no. 1, pp. 101–109,
2009.
[10] A. Flower, J. P. Liu, G. Lewith, P. Little, and Q. Li, “Chinese
herbal medicine for endometriosis,” Cochrane Database of
Systematic Reviews, vol. 5, p. CD006568, 2012.
[11] J. Abbott, J. Hawe, D. Hunter, M. Holmes, P. Finn, and R.
Garry, “Laparoscopic excision of endometriosis: a randomized,
placebo-controlled trial,” Fertility and Sterility, vol. 82, no. 4, pp.
878–884, 2004.
[12] F. Wieser, M. Cohen, A. Gaeddert et al., “Evolution of medical
treatment for endometriosis: back to the roots?”Human Repro-
duction Update, vol. 13, no. 5, pp. 487–499, 2007.
[13] A. Flower, G. T. Lewith, and P. Little, “Seeking an oracle:
using the Delphi process to develop practice guidelines for the
treatment of endometriosis with Chinese herbal medicine,”The
Journal of Alternative and Complementary Medicine, vol. 13, no.
9, pp. 969–976, 2007.
[14] R.-C. Fang, Y.-T. Tsai, J.-N. Lai, C.-H. Yeh, and C.-T. Wu,
“The Traditional Chinese Medicine Prescription Pattern of
Endometriosis Patients in Taiwan: A Population-Based Study,”
Evidence-Based Complementary and Alternative Medicine, vol.
2012, Article ID 591391, 9 pages, 2012.
[15] N. N. Chen, M. Han, H. Yang et al., “Chinese herbal medicine
Guizhi Fuling Formula for treatment of uterine fibroids: a sys-
tematic review of randomised clinical trials,” BMC Complement
Altern Med, vol. 14, no. 2, 2014.
[16] T. Ushiroyama, A. Ikeda, K. Sakuma, andM. Ueki, “Comparing
the effects of estrogen and an herbal medicine on peripheral
blood flow in post-menopausal women with hot flashes: Hor-
mone replacement therapy and Gui-zhi-fu-ling-wan, a kampo
medicine,” American Journal of Chinese Medicine, vol. 33, no. 2,
pp. 259–267, 2005.
[17] K. Nozaki, H. Hikiami, H. Goto, T. Nakagawa, N. Shibahara,
and Y. Shimada, “Keishibukuryogan (Gui-Zhi-Fu-Ling-Wan), a
Kampo formula, decreases disease activity and soluble vascular
adhesion molecule-1 in patients with rheumatoid arthritis,”
Evidence-Based Complementary and Alternative Medicine, vol.
3, no. 3, pp. 359–364, 2006.
[18] X. Zhang, A. Sandhu, I. Edirisinghe, and B. Burton-Freeman,
“An exploratory study of red raspberry (: Rubus idaeus L.)
(poly)phenols/metabolites in human biological samples,” Food
& Function, vol. 9, no. 2, pp. 806–818, 2018.
[19] M. A. Farag, N. M. Ammar, T. E. Kholeif et al., “Rats’ urinary
metabolomes reveal the potential roles of functional foods and
exercise in obesity management,” Food & Function, vol. 8, no. 3,
pp. 985–996, 2017.
[20] S. K. Jana, M. Dutta, M. Joshi, S. Srivastava, B. Chakravarty,
and K. Chaudhury, “1H NMR Based Targeted Metabolite
Profiling for Understanding the Complex Relationship Con-
necting Oxidative Stress with Endometriosis,” BioMed Research
International, vol. 2013, Article ID 329058, 9 pages, 2013.
[21] A. I. Frolova and K. H. Moley, “Glucose transporters in
the uterus: An analysis of tissue distribution and proposed
physiological roles,” Reproduction, vol. 142, no. 2, pp. 211–220,
2011.
[22] F. Qu, J. Zhou, and B. Ma, “The effect of Chinese herbs on the
cytokines of rats with endometriosis,”The Journal of Alternative
and Complementary Medicine, vol. 11, no. 4, pp. 627–630, 2005.
[23] Z.-H. Zhou, Q. Weng, J.-H. Zhou, and J. Zhou, “Extracts of
Salvia miltiorrhiza bunge on the cytokines of rat endometriosis
models,” African Journal of Traditional, Complementary and
Alternative Medicines, vol. 9, no. 3, pp. 303–314, 2012.
Evidence-Based Complementary and Alternative Medicine 9
[24] Q. Weng, Z.-F. Cao, Y.-W. Yu, X.-L. Lv, F. Qu, and J. Zhou, “The
effects of extracts of atractylodesmacrocephala koidz combined
with transcutaneous electrical acupoint stimulation in treating
the ovariectomized female rats,” African Journal of Traditional,
Complementary and Alternative Medicines, vol. 13, no. 2, pp.
243–249, 2016.
[25] J. Shi, Z. B. Z. Ge, Y. Jin, Y. D. Li, and J. Zhou, “Acupuncture
improves the effects of chinese herbal medicine in treating
endometriosis model rats,” The Journal of Animal & Plant
Sciences, vol. 1, pp. 298–303, 23.
[26] W. G. Schoonen, C. P. Kloks, J. H. Ploemen et al., “Uniform Pro-
cedure of 1H NMR Analysis of Rat Urine and Toxicometabo-
nomics Part II: Comparison of NMR Profiles for Classification
of Hepatotoxicity,”Toxicological Sciences, vol. 98, no. 1, pp. 286–
297, 2007.
[27] B. Koczor and J. Rohonczy, “PICmicrocontroller based external
fast analog to digital converter to acquire wide-lined solid NMR
spectra by BRUKER DRX and Avance-I spectrometers,” Solid
State Nuclear Magnetic Resonance, vol. 66, pp. 21–28, 2015.
[28] X. Liu, W. Zhu, S. Guan et al., “Metabolomic analysis of anti-
hypoxia and anti-anxiety effects of Fu Fang Jin Jing oral liquid,”
PLoS ONE, vol. 8, no. 10, Article ID e78281, 2013.
[29] B. McKinnon, D. Bertschi, C. Wotzkow, N. A. Bersinger, J.
Evers, and M. D. Mueller, “Glucose transporter expression in
eutopic endometrial tissue and ectopic endometriotic lesions,”
Molecular Endocrinology, vol. 52, no. 2, pp. 169–179, 2014.
[30] V. J. Young, S. F. Ahmad, J. K. Brown, W. C. Duncan, and A.
W. Horne, “ID2 mediates the transforming growth factor-𝛽1-
induced Warburg-like effect seen in the peritoneum of women
with endometriosis,” Molecular Human Reproduction, vol. 22,
no. 9, pp. 648–654, 2016.
[31] F. Hirschhaeuser, U. G. A. Sattler, and W. Mueller-Klieser,
“Lactate: ametabolic key player in cancer,”Cancer Research, vol.
71, no. 22, pp. 6921–6925, 2011.
[32] B. Czarkowska-Paczek, I. Bartlomiejczyk, and J. Przybylski,
“The serum levels of growth factors: PDGF, TGF-beta and
VEGF are increased after strenuous physical exercise,” Journal
















































































Submit your manuscripts at
www.hindawi.com
